OBJECTIVES

: Assess changes in HF symptoms and referrals to hospital among patients treated with sacubitril/valsartan (sac/val) in the primary care (PC) and cardiologist setting in Germany.

METHODS

: Electronic medical records from 1108 PC and 41 Cardiologist practices from the German IMS Disease Analyzer database identified patients (≥18 years) with a sac/val prescription (Rx) between 01/01/2016 and 31/12/2016, from practices with continuous data delivery since study initiation (01/01/2015), and with minimum 6 months of post-index data available (min 1 Rx following index date). Baseline characteristics were defined during the 12 months pre-index. The following HF signs and symptoms were evaluated during 90 days pre-index and 31-120 post-index (allowing for 30 days up-titration) through ICD-10 codes and free text searches: dyspnoea, pulmonary oedema, peripheral oedema, fatigue, chest pain, nausea, cough. McNemar’s and Wilcoxon signed-rank test were used to compare pre- and post-index periods for the same patients.

RESULTS

: CONCLUSIONS

: Fewer HF symptoms and referrals to hospital (all-cause) were observed after treatment with sac/val, consistently across specialty and sac/val dose levels at index.